Reyataz - Bristol-myers | Article One Partners
One moment please.

You are using unknown unknown. Some features may not be supported and the experience may be degraded using an older browser.

industry icon Reyataz - Bristol-myers

These patents cover the drug REYATAZ. It is used to treat HIV, which causes acquired immunodeficiency syndrome (AIDS).

Description

The active ingredient of REYATAZ is atazanavir sulfate.

The patents relate to the structure, compositions, formulations and methods of use of atazanavir sulfate.
Name of Substance
Atazanavir
Atazanavir [INN:BAN]
BMS 232632

Synonyms
ATV
ATZ
Atazanavir
CGP 73547
HSDB 7339
Latazanavir
UNII-QZU4H47A3S
Zrivada

Systematic Name
2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester,
(3S,8S,9S,12S)-2,5,6,10,13-Pentaazatetradecanedioic acid, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-, dimethyl ester, (3S-(3R*,8R*,9R*,12R*))-

In allowing the claims of the ‘911 patent, the examiner wrote:
“Claims 1-11 are allowed. The closest prior art is Fassler et al. (J. Med. Chem. 1996, vol. 39, pages 3203-3216) disclose aza-peptide analogs as potent Human Immunodeficiency Virus Type-1 Protease Inhibitors with oral bioavailability.
The instant claims differ from the reference in having the substituted phenyl group at R4 position, whereas the reference teach [sic] unsubstituted phenyl group at the same position. This difference was neither taught or suggested by the prior art of record.” 

Research Requirements:

Latest Date for Responses
1995-04-21
Relevant Patent Dates
US Patent Date
Filing Date
US Application Date
Filing Date
EP Date
Publication Date
Other Patent Authorities
Publication Date
See the claims in the downloadable copies of the patents.